Hanson Pharmaceuticals (03692): The B7-H3 targeted antibody drug conjugate HS-20093 was recognized as a breakthrough therapy by the FDA for late-line recurrent or refractory osteosarcoma

Zhitongcaijing · 6d ago

Zhitong Financial App News, Hanson Pharmaceuticals (03692) announced that GSK has been granted breakthrough therapy certification (BTD) by the US Food and Drug Administration (FDA) for GSK5764227 (GSK'227). This B7-H3 targeted antibody drug conjugate (ADC) is being evaluated for treating adult patients with recurrent or refractory osteosarcoma (bone cancer) with previous second-line treatment progression. HS-20093

HS-20093 is a novel B7-H3 targeting ADC, formed by covalently linking an all-human anti-B7-H3 monoclonal antibody with a topoisomerase inhibitor (topoI) payload. Multiple phase I, phase II, and phase III clinical studies for the treatment of lung cancer, sarcoma, head and neck cancer, and other solid tumors are being carried out in China.